26 September 2013 | Regulatory | By BioSpectrum Bureau
The CFDA approval for the DSX system is effective for four years
Singapore: Dynex Technologies received approval from China's Food and Drug Administration (CFDA) to market the DSX automated enzyme-linked immunosorbent assay (ELISA) processing system in China.
The DSX is Dynex's industry leading automated ELISA processing system for diagnostic assays in clinical laboratories, capable of quickly and accurately handling four microplates per assay run, greatly reducing required manual technician time while improving the speed and reliability of test results.
The CFDA approval for the DSX system is effective for four years and allows Dynex to provide broader automation options to assay developers and clinical technologists throughout China.